Score
4
2025
pubmed
In adults with obesity but without type 2 diabetes, tirzepatide increased weight loss at 72 wk compared with semaglutide.
Lesser. Lenard I LI
Key Findings
- Tirzepatide produced greater total body weight loss than semaglutide after 72 weeks in obese adults without diabetes
- Both drugs were generally well‑tolerated, with safety profiles similar to previous studies
- The benefit was seen across a range of doses, indicating dose‑flexibility for individual needs
Practical Outcomes
- For biohackers and self‑experimenters, tirzepatide appears to be a more potent option for weight loss than semaglutide. It could be considered for off‑label use under medical supervision, with attention to dosing schedules that match the study (e.g., weekly injections). Monitoring for typical GI side effects and regular health checks remain important.
Summary
A study in people who are overweight but don’t have diabetes found that tirzepatide helped them lose more weight over about a year and a half than the already‑popular drug semaglutide. The trial lasted 72 weeks and showed a clear advantage for tirzepatide without major safety concerns, suggesting it could be a stronger tool for weight‑loss and metabolic health.
Abstract
GIM/FP/GP: [Formula: see text] Endocrinology: [Formula: see text].
Study Information
Provider
pubmed
Year
2025
Date
2025-11-04T00:00:00.000Z
DOI
10.7326/annals-25-04321-jc